In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2

Experimental Hematology

Volumn 39, Issue 1, 2011, Pages 14-25

  Riaz Ahmed, Kausar Begam ^a   Warner, Steven L ^b   Chen, Andrew ^a   Gourley, Eric S ^b   Liu, Xiaohui ^b   Vankayalapati, Hariprasad ^b   Nussenzveig, Roberto ^c   Prchal, Josef T ^a   Bearss, David J ^b   Parker, Charles J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Supergen Inc   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; PHENYLALANINE; PROTEIN BCL XL; SGI 1252; STAT5 PROTEIN; UNCLASSIFIED DRUG; VALINE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG STRUCTURE; ENZYME INHIBITION; ERYTHROID PRECURSOR CELL; ERYTHROLEUKEMIA; EX VIVO STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; MYELOFIBROSIS; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE; CELL PROLIFERATION; DIAMINES; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; JANUS KINASE 2; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

MURINAE;

EID: 78650198723     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.09.013     Document Type: Article

References (42)

1. Kutti J., Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol (Paris) 2001, 49:164-166.
2. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005, 105:4187-4190.
3. Kilpivaara O., Levine R.L. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008, 22:1813-1817.
4. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372-375.
5. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
6. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
7. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
8. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
9. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788-22792.
10. Scott L.M., Scott M.A., Campbell P.J., Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 108:2435-2437.
11. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108:1652-1660.
12. Tiedt R., Hao-Shen H., Sobas M.A., et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111:3931-3940.
13. Quentmeier H., MacLeod R.A., Zaborski M., Drexler H.G. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006, 20:471-476.
14. Jones A.V., Bunyan D.J., Cross N.C. No evidence for amplification of V617F JAK2 in myeloproliferative disorders. Leukemia 2007, 21:2561-2563.
15. Nussenzveig R.H., Swierczek S.I., Jelinek J., et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007, 35:32-38.
16. Gaikwad A., Nussenzveig R., Liu E., Gottshalk S., Chang K., Prchal J.T. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol 2007, 35:587-595.
17. Gaikwad A., Prchal J.T. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera. Exp Hematol 2007, 35:1647-1656.
18. Freeman W.M., Walker S.J., Vrana K.E. Quantitative RT-PCR: pitfalls and potential. Biotechniques 1999, 26:112-122. 124-115.
19. Valentino L., Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006, 71:713-721.
20. Socolovsky M., Fallon A.E., Wang S., Brugnara C., Lodish H.F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98:181-191.
21. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 2005, 333:336-343.
22. Baker S.J., Rane S.G., Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 2007, 26:6724-6737.
23. Levine R.L., Gilliland D.G. Myeloproliferative disorders. Blood 2008, 112:2190-2198.
24. Russell S.M., Tayebi N., Nakajima H., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270:797-800.
25. Macchi P., Villa A., Giliani S., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68.
26. Minegishi Y., Saito M., Morio T., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006, 25:745-755.
27. Rodig S.J., Meraz M.A., White J.M., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
28. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
29. Hexner E.O., Serdikoff C., Jan M., et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008, 111:5663-5671.
30. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-3676.
31. Tefferi A. JAK Inhibitors in myeloproliferative neoplasms. The Hematologist: ASH News and Reports 2010, 7:5.
32. Wadleigh M., Tefferi A. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors. Clin Adv Hematol Oncol 2010, 8:557-563.
33. Vander Heiden M.G., Chandel N.S., Williamson E.K., Schumacker P.T., Thompson C.B. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997, 91:627-637.
34. Kuwana T., Newmeyer D.D. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003, 15:691-699.
35. Sedlak T.W., Oltvai Z.N., Yang E., et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A 1995, 92:7834-7838.
36. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995, 80:285-291.
37. Biswas R.S., Cha H.J., Hardwick J.M., Srivastava R.K. Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL. Mol Cell Biochem 2001, 225:7-20.
38. Verstovsek S., Kantarjian H.M., Pardanani A.D., et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F: WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB018424. ASH Annual Meeting Abstracts 2008, 112:2802.
39. Verstovsek S., Kantarjian H.M., Pardanani A.D., et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post PV/ETMF). Blood (ASH Annual Meeting Abstracts) 2008, 112:1762.
40. Pardanani A.D., Gotlib J., Jamieson C., et al. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood (ASH Annual Meeting Abstracts) 2008, 112:97.
41. Mesa R.A., Verstovsek S., Kantarjian H.M., et al. INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts) 2008, 112:1760.
42. Santos F.P., Kantarjian H.M., Jain N., et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115:1131-1136.